Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
Joyce O'ShaughnessyJavier CortesChris TwelvesLori J GoldsteinKarenza AlexisRan XieCarlos Henrique BarriosTakayuki UenoPublished in: Scientific reports (2020)
Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin compared with control in patients with bone, lymph node, and chest wall/breast/skin metastases at baseline was observed. Additionally, a difference in OS was also seen in patients with liver metastases randomized to eribulin versus control (median: 13.4 versus 11.3 months, respectively; hazard ratio, 0.84 [95% CI: 0.72, 0.97]). Results of this exploratory analysis suggest that eribulin may be efficacious for the treatment of locally advanced/MBC for patients with bone, liver, lung, lymph node, and chest wall/breast/skin metastases.
Keyphrases
- metastatic breast cancer
- locally advanced
- neoadjuvant chemotherapy
- lymph node
- squamous cell carcinoma
- rectal cancer
- free survival
- radiation therapy
- estrogen receptor
- phase ii study
- soft tissue
- end stage renal disease
- open label
- double blind
- liver metastases
- phase ii
- chronic kidney disease
- bone mineral density
- phase iii
- small cell lung cancer
- ejection fraction
- sentinel lymph node
- placebo controlled
- clinical trial
- skeletal muscle
- postmenopausal women
- peritoneal dialysis
- adipose tissue
- combination therapy
- smoking cessation
- patient reported